person · Reporting owner

DAWES KAREN A

Disclosed activity across 3 companies

Tapewire entity: 46694
SEC CIK: 0001261506

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Assertio Therapeutics, IncASRT · Entity 149352	Director	May 08, 2020	May 12, 2020
REPLIGEN CORPRGEN · Entity 486	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Assertio Therapeutics, Inc

Report date May 08, 2020 · Filed May 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	84,589	Reported balance After 2020-05-08 transaction · row 1 1 source row Row 1 · 2020-05-08 · Sale · Disposed 15,834 · Balance 84,589 F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019.

F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.

REPLIGEN CORP

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	92,816	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 995 · Balance 92,816 F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14	Direct	2,239	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Filing footnotes · ownership attribution and instrument terms

F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Barinthus Biotherapeutics plc.

Report date September 09, 2026 · Filed September 09, 2026

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2026-09-09 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-09 · Disposition to issuer · Disposed 1,700 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-05-01	Direct	Reported balance After 2026-09-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-09 · Disposition to issuer · Disposed 34,328 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-15	Direct	Reported balance After 2026-09-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-09 · Disposition to issuer · Disposed 18,604 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2033-05-11	Direct	Reported balance After 2026-09-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-09 · Disposition to issuer · Disposed 19,197 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2034-05-10	Direct	Reported balance After 2026-09-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-09 · Disposition to issuer · Disposed 19,516 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-06-10	Direct	Reported balance After 2026-09-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-09 · Disposition to issuer · Disposed 20,174 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.

F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco.

F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerShare Option (Right to Buy) · Derivative	20,174	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · derivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,174 shares Expires 2035-06-10 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerShare Option (Right to Buy) · Derivative	19,516	$0.00 Strike: $2.34	$0.00	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · derivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,516 shares Expires 2034-05-10 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerShare Option (Right to Buy) · Derivative	19,197	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · derivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 19,197 shares Expires 2033-05-11 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerShare Option (Right to Buy) · Derivative	18,604	$0.00 Strike: $4.27	$0.00	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,604 shares Expires 2032-06-15 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerShare Option (Right to Buy) · Derivative	34,328	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,328 shares Expires 2031-05-01 F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. Read SEC document
September 09, 2026 Filed Sep 9, 2026 20:15 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	Disposition to issuerOrdinary Shares	1,700	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-106323 · tm2625057-1_4seq1.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2 · kind: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3 · shares: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). F3 · price: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock"). Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	2,239	$0.00 Strike: $103.38	$0.00	Disclosure SEC source: 0001193125-26-228884 · ownership.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 14, 2026 Filed May 18, 2026 20:05 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	995	$0.00	$0.00	Disclosure SEC source: 0001193125-26-228884 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,816 F1 · shares: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
December 17, 2025 Filed Dec 18, 2025 21:30 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	275	$161.00	$44,275.00	Disclosure SEC source: 0001193125-25-324912 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,821 Read SEC document
June 10, 2025 Filed Jun 11, 2025 17:10 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	GrantShare Option (Right to Buy) · Derivative	20,174	$0.00 Strike: $1.00	$0.00	Disclosure SEC source: 0001828185-25-000039 · wk-form4_1749676222.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,174 Underlying: Ordinary Shares · 20,174 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 15, 2025 Filed May 19, 2025 19:27 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,800	$0.00 Strike: $123.26	$0.00	Disclosure SEC source: 0000950170-25-074251 · ownership.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2035-05-15 F2 · derivative.exercise_date: Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 15, 2025 Filed May 19, 2025 19:27 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	973	$0.00	$0.00	Disclosure SEC source: 0000950170-25-074251 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,096 F1 · shares: Ms. Dawes was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
June 14, 2024 Filed Jun 14, 2024 21:33 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	2,953	$0.00 Strike: $67.71	$0.00	Disclosure SEC source: 0000950170-24-073829 · ownership.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,953 shares Expires 2029-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
June 14, 2024 Filed Jun 14, 2024 21:33 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	2,953	$67.71	$199,947.63	Disclosure SEC source: 0000950170-24-073829 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 16, 2024 Filed May 20, 2024 22:50 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,576	$0.00 Strike: $171.03	$0.00	Disclosure SEC source: 0000950170-24-062599 · ownership.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576 Underlying: Common Stock · 1,576 shares Expires 2034-05-16 F2 · derivative.exercise_date: Award vests in full on the earlier of May 16, 2025, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 16, 2024 Filed May 20, 2024 22:50 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	803	$0.00	$0.00	Disclosure SEC source: 0000950170-24-062599 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,170 F1 · shares: Ms. Dawes was awarded 803 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 16, 2025, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 10, 2024 Filed May 14, 2024 16:23 UTC	Barinthus Biotherapeutics plc. BRNS · Entity 9597	GrantShare Option (Right to Buy) · Derivative	19,516	$0.00 Strike: $2.34	$0.00	Disclosure SEC source: 0001828185-24-000058 · wk-form4_1715718176.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,516 Underlying: Ordinary Shares · 19,516 shares Expires 2034-05-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 27, 2024 Filed Feb 29, 2024 02:56 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	4,626	$0.00 Strike: $42.07	$0.00	Disclosure SEC source: 0000950170-24-022581 · ownership.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,626 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
February 27, 2024 Filed Feb 29, 2024 02:56 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,000	$193.35	$193,350.00	Disclosure SEC source: 0000950170-24-022581 · ownership.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,367 Read SEC document
February 27, 2024 Filed Feb 29, 2024 02:56 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	4,626	$42.07	$194,615.82	Disclosure SEC source: 0000950170-24-022581 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 29, 2023 Filed Aug 30, 2023 20:06 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	7,392	$0.00 Strike: $18.12	$0.00	Disclosure SEC source: 0000950170-23-045417 · ownership.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,392 shares Expires 2024-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
August 29, 2023 Filed Aug 30, 2023 20:06 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	850	$171.38	$145,673.00	Disclosure SEC source: 0000950170-23-045417 · ownership.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,741 F1 · price: $171.38 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.37 to $171.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 29, 2023 Filed Aug 30, 2023 20:06 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	7,392	$18.12	$133,943.04	Disclosure SEC source: 0000950170-23-045417 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 18, 2023 Filed May 23, 2023 01:26 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,730	$0.00 Strike: $156.63	$0.00	Disclosure SEC source: 0000899243-23-013671 · doc4.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,730 Underlying: Common Stock · 1,730 shares Expires 2033-05-18 F2 · derivative.exercise_date: Award vests in full on the earlier of May 18, 2024, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 18, 2023 Filed May 23, 2023 01:26 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	798	$0.00	$0.00	Disclosure SEC source: 0000899243-23-013671 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,199 F1 · shares: Ms. Dawes was awarded 798 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 18, 2024, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 11, 2023 Filed May 12, 2023 16:05 UTC	Barinthus Biotherapeutics plc. VACC · Entity 9597	GrantShare Option (Right to Buy) · Derivative	19,197	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001104659-23-059712 · tm2315647-1_4seq1.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,197 Underlying: Ordinary Shares · 19,197 shares Expires 2033-05-11 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
September 09, 2022 Filed Sep 9, 2022 20:14 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	775	$227.17	$176,056.75	Disclosure SEC source: 0000899243-22-030728 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,401 F1 · price: $227.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.12 to $227.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 15, 2022 Filed Feb 10, 2023 16:34 UTC	Barinthus Biotherapeutics plc. VACC · Entity 9597	GrantShare Option (Right to Buy) · Derivative	18,604	$0.00 Strike: $4.27	$0.00	Disclosure SEC source: 0001104659-23-018593 · tm236344-1_5seq1.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,604 Underlying: Ordinary Shares · 18,604 shares Expires 2032-06-15 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 26, 2022 Filed Jun 1, 2022 00:21 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,565	$0.00 Strike: $159.17	$0.00	Disclosure SEC source: 0000899243-22-020280 · doc4.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,565 Underlying: Common Stock · 1,565 shares Expires 2032-05-26 F2 · derivative.exercise_date: Award vests in full on the earlier of May 26, 2023, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 26, 2022 Filed Jun 1, 2022 00:21 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	644	$0.00	$0.00	Disclosure SEC source: 0000899243-22-020280 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,176 F1 · shares: Ms. Dawes was awarded 644 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 26, 2023, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 25, 2022 Filed May 26, 2022 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	742	$152.84	$113,407.28	Disclosure SEC source: 0000899243-22-019772 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,532 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F6 · price: $152.84 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.69 to $153.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 25, 2022 Filed May 26, 2022 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,875	$152.14	$285,262.50	Disclosure SEC source: 0000899243-22-019772 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,274 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $152.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.63 to $152.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 25, 2022 Filed May 26, 2022 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,845	$151.14	$278,853.30	Disclosure SEC source: 0000899243-22-019772 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,149 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $151.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.63 to $151.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 25, 2022 Filed May 26, 2022 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	7,677	$150.19	$1,153,008.63	Disclosure SEC source: 0000899243-22-019772 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,994 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $150.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.62 to $150.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 25, 2022 Filed May 26, 2022 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	2,576	$149.18	$384,287.68	Disclosure SEC source: 0000899243-22-019772 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,671 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $149.18 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.61 to $149.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	4,783	$0.00 Strike: $26.12	$0.00	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · derivative · entry 12 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,783 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	14	$271.28	$3,797.92	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 11 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,247 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	255	$269.94	$68,834.70	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 10 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,261 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F10 · price: $269.94 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.44 to $270.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	349	$267.75	$93,444.75	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 9 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,516 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F9 · price: $267.75 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.49 to $268.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	486	$266.72	$129,625.92	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 8 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,865 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F8 · price: $266.72 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.15 to $267.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	488	$265.27	$129,451.76	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,351 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F7 · price: $265.27 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.95 to $265.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	336	$264.21	$88,774.56	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,839 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F6 · price: $264.21 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.89 to $264.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,119	$263.23	$294,554.37	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,175 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $263.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.82 to $263.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,038	$262.28	$272,246.64	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,294 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $262.28 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.68 to $262.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	236	$261.10	$61,619.60	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,332 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $261.10 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.65 to $261.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	462	$259.75	$120,004.50	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,568 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $259.75 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.32 to $260.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 10, 2021 Filed Nov 12, 2021 22:12 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	4,783	$26.12	$124,931.96	Disclosure SEC source: 0000899243-21-044418 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	283	$306.49	$86,736.67	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,247 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F7 · price: $306.49 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $306.40 to $307.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	700	$305.91	$214,137.00	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,530 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F6 · price: $305.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.24 to $306.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	124	$304.23	$37,724.52	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,230 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $304.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $304.01 to $304.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.